July 29, 2010 GSK Exercises Option On Anacor's Novel Antibiotic For The Treatment Of Gram-Negative Infections
June 15, 2010 AN3365, A Novel Antibiotic Intended to Treat Infections Caused by Gram-Negative Bacteria, Completes Phase 1 Trial and Achieves Proof of Concept in Collaboration with GSK
June 15, 2010 Anacor Announces Phase 2b Top-Line Results For AN2728 In Psoriasis
April 26, 2010 Medicines for Malaria Venture and Anacor Pharmaceuticals Announce Collaboration to Apply Boron Chemistry Technology to Identify New Medicines for the Treatment of Malaria
March 3, 2010 Anacor To Present At Cowen And Company Health Care Conference
February 12, 2010 Anacor Regains Worldwide Rights To An2690 From Merck
January 28, 2010 Anacor To Present Preclinical Data On Orally Active Pde4 Inhibitor At The 8th Cytokines And Inflammation Conference
January 11, 2010 Anacor To Present At J.P. Morgan Healthcare Conference
2009
November 17, 2009 Anacor Initiates Phase I Clinical Development For AN3365 – A Novel Antibiotic For The Treatment Of Gram-negative Infections
June 10, 2009 Anacor Co-Founders Recognized For Scientific Achievements
June 2, 2009 Anacor To Present At Needham Life Sciences Conference
May 27, 2009 Anacor Announces Collaborations with TB Alliance and DNDi to Apply Boron Technology to Identify New Medicines for Neglected Diseases
March 10, 2009 Anacor To Present At Cowen And Company Health Care Conference
March 6, 2009 Anacor Announces Positive Results from Phase 1 Safety Trial of AN2898 for Psoriasis and Atopic Dermatitis
March 4, 2009 Anacor Announces Positive Results from Phase 1 Trial of AN2718
March 2, 2009 Anacor To Present Clinical and Preclinical Data On Topical Anti-Inflammatory and Anti-Fungal Candidates, AN2728, AN2898 and AN2718, At The American Academy Of Dermatology Annual Meeting
February 19, 2009 Anacor Announces Positive Results from Phase 2 Psoriasis Trial
January 12, 2009 Anacor Achieves Milestone from GSK for Boron-Based Systemic Antibacterial Product Candidate
January 6, 2009 Anacor Raises $50 Million in Equity Financing - Investments from GlaxoSmithKline, Schering Corporation and Existing Investors
2008
August 4, 2008 Anacor Pharmaceuticals Appoints Dr. Kurt Jarnagin Vice President Of Biological Research
May 8, 2008 Anacor To Present Clinical And Preclinical Data On Topical Anti-Inflammatory Candidates, AN2728 And AN2898, At The International Investigative Dermatology 2008 Conference
March 25, 2008 Anacor Pharmaceuticals Announces Positive Results from Phase 2a Clinical Trial of AN2728 in Psoriasis Patients
2007
October 8, 2007
GlaxoSmithKline and Anacor Pharmaceuticals Form Alliance to Develop Systemic Antivirals and Antibiotics
Based on Boron Chemistry
October 1, 2007
Anacor Pharmaceuticals Appoints Paul Cleveland to its Board of Directors and Chairman of its Audit Committee
August 31, 2007
Anacor Files Registration Statement for Initial Public Offering
July 18, 2007
Anacor Names Christine Gray-Smith Chief Financial Officer
June 21, 2007
Anacor Identifies a Novel Mechanism for its Lead Anti-Fungal Drug, AN2690; Findings Published in Science
June 6, 2007
Anacor Clinical Study of AN2728, A Novel Anti-Inflammatory Compound, Shows Efficacy in Psoriasis
August 9, 2006
Anacor Releases Data Showing Clinical Safety of Topical Antifungal Treatment
June 15, 2006
Anacor Announces Positive Results from Phase 2 Trial of Novel Anti-Inflammatory Agent for the
Treatment of Atopic Dermatitis
May 4, 2006
Anacor Presents Data on Novel Mechanism of Action for its Topical Antifungal Treatment,
AN2690
View Posters: #769, #775, #750
April 19, 2006
Anacor Interim Phase 2 Study Results Show AN2690 Penetrates Nail Bed, Kills Fungi to Successfully
Treat Nail Infections View Poster
March 3, 2006
Anacor Announces Positive Phase 1 and Preclinical Data for Novel Topical Atopic Dermatitis Agent
March 1, 2006
Anacor Announces Nine Poster Presentations for Its Two Lead Product Candidates at the American Academy
of Dermatology 64th Annual Meeting View Posters
2005
May 11, 2005
Anacor Pharmaceuticals Raises $25 Million in Series C Financing
May 11, 2005
Life Sciences Industry Veterans Join Anacor Pharmaceuticals Board of Directors
April 25, 2005
Dr. Karl Beutner Appointed Chief Medical Officer of Anacor Pharmaceuticals
2004
March 1, 2004
Anacor Pharmaceuticals Names Dr. Jacob J. Plattner Head of Research
2002
October 29, 2002
Anacor Pharmaceuticals Formed to Develop New Class of Therapeutics
October 29, 2002
Anacor Pharmaceuticals Raises $7 Million in Venture Financing
October 29, 2002
Anacor Pharmaceuticals Receives $21.6 Million Contract from Department of Defense
